Treatment of scalp psoriasis: Review of the evidence and Delphi consensus of the psoriasis group of the Spanish academy of dermatology and venereology;Tratamiento de la psoriasis del cuero cabelludo. Revisión de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología

Actas Dermo-Sifiliograficas

Volumn 101, Issue 10, 2010, Pages 827-846

  Puig, L ^a   Ribera, M ^b   Hernanz, J M ^c   Belinchon I ^d   Santos Juanes, J ^e   Linares, M ^f   Querol, I ^g   Colome E ^h   Caballe G ⁱ  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Hospital Universitari de Sabadell   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^g UNIVERSITY OF ZARAGOZA   (Spain)

^h Departamento Médico   (Spain)

ⁱ Departamento de Ventas y Marketing   (Spain)

Author keywords

Calcipotriol; Delphi; Process; Psoriasis; Scalp; Topical corticosteroids; Treatment

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID;

CONFERENCE PAPER; DELPHI STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; PATIENT COMPLIANCE; PSORIASIS; SKIN DISEASE;

EID: 78649238201     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(10)70730-7     Document Type: Conference Paper

References (109)

1. E.M. Farber, and L. Nail Natural history and treatment of scalp psoriasis Cutis 49 1992 396 400
2. P.C. Van de Kerkhof, and M.E. Franssen Psoriasis of the scalp. Diagnosis and Management Am J Clin Dermatol 2 2001 159 165
3. J. Sola-Ortigosa, M. Sánchez-Regaa, and P. Umbert-Millet Psoriasis del cuero cabelludo Actas Dermosifiligr 100 2009 536 543
4. P.C. Van de Kerkhof, D. de Hoop, J. de Korte, and M.V. Kuipers Scalp psoriasis, clinical presentations and therapeutic management Dermatology 197 1998 326 334
5. V.M. Heydendael, C.A. de Borgie, P.L. Spuls, P.M. Bossuyt, J.D. Bos, and M.A. de Rie The burden of psoriasis is not determined by disease severity only J Investig Dermatol Symp Proc 9 2004 131 135
6. R. Harbour, J. Miller for the Scottish Intercollegiate Guidelines Network Grading Review Group A new system for grading recommendations in evidence based guidelines BMJ 323 2001 334 336
7. C.S. Chan, A.S. Van Voorhees, M.G. Lebwohl, N.J. Korman, M. Young, and B.F. Bebo Treatment of severe scalp psoriasis: from the medical board of the National Psoriasis Foundation J Am Acad Dermatol 60 2009 962 971
8. K. Papp, J. Berth-Jones, K. Kragballe, G. Wozel, and de la Brassinne Scalp psoriasis: a review of current topical treatments options J Eur Acad Dermatol Venereal 21 2007 1151 1160
9. A.R. Mason, J. Mason, M. Cork, G. Dooley, and G. Edwards Topical treatments for chronic plaque psoriasis Cochrane Database Sys Rev 2009 CD005028
10. J. Ortonne, S. Chimenti, T. Luger, L. Puig, F. Reid, and R. Treb Scalp psoriasis: European consensus on grading and treatment algorithm J Eur Acad Dermatol Venereol 23 2009 1435 1444
11. J. Jones, and D. Hunter Consensus methods for medical and health services research BMJ 311 1995 376 380
12. D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, and S. Flottorp Grading quality of evidence and strength of recommendations BMJ 328 2004 1490
13. G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, and P. Alonso-Coello GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recomendations BMJ 336 2008 924 926
14. T. Frederiksson, and U. Pettersson Severe psoriasisoral therapy with a new retinoid Dermatologica 157 1978 238 244
15. K. Reich, and U. Mrowietz Treatment goals in psoriasis J Dtsch Dermatol Ges 5 2007 566 574
16. D. Thai, W. Daiber, W.H. Boehncke, and R. Kaufmann Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3396 patients Dermatology 203 2001 153 156
17. J. Choi, and J.Y. Koo Quality of life issues in psoriasis J Am Acad Dermatol 49 Supl 2 2003 S57 S61
18. Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-36 Health Survey. Qualitymetric Incorporated, Lincoln, Rhode Island 2000.
19. M. Jones-Caballéero, P. Fernndez- Peas, A. García-Dez, M.M. Chren, and X. Bada La versin espaola de Skindex-29. Un instrumento de medida de la calidad de vida en pacientes con enfermedades cutneas Med Clin (Barc) 118 2002 5 9
20. S.C. Chen, J. Yeung, and M.M. Chren Scalpdex: a quality-of-life instrument for scalp dermatitis Arch Dermatol 138 2002 803 807
21. M. Lebwohl A clinician's paradigm in the treatment of psoriasis J Am Acad Dermatol 53 Supl 1 2005 S59 S69
22. J.E. Frangos, and A.B. Kimball Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses Expert Opin Pharmacother 9 2008 2001 2007
23. M.I. Lepaw Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp Cutis 21 1978 571 573
24. E.A. Olsen, D.L. Cram, J.G. Hickman, C. Jacobson, E.E. Jenkins, and A.E. Lasser A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis J Am Acad Dermatol 24 1991 443 447
25. M. Pauporte, H. Maibach, N. Lowe, M. Pugliese, D.J. Friedman, and H. Mendelsohn Fluocinolone acetonide topical oil for scalp psoriasis J Dermatolog Treat 15 2004 360 364
26. M. Jarrat, D. Breneman, A.B. Gottlieb, Y. Poulin, Y. Liu, and V. Foley Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to sever scalp psoriasis J Drugs Dermatol 3 2004 367 373
27. T.J. Franz, D.A. Parsell, R.M. Halualani, J.F. Hannigan, J.P. Kalbach, and S. Harkonen Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy Int J Dermatol 38 1999 628 632
28. L. Andreassi, A. Giannetti, and M. Milani Efficacy of betamethasone valerate mouse in comparison with standard therapies on scalp psoriasis. An open, multicentre, randomized, controlled, cross-over study on 241 patients Br J Dermatol 148 2003 134 138
29. H.I. Katz, J.S. Lindholm, J.S. Weiss, J.S. Shavin, M. Morman, and R. Bressinck Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis Clin Ther 17 1995 390 401
30. D.L. Breneman, M. Davis, V. Berger, and R. Chaney A double blind comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis J Dermatol Treat 3 1992 19 21
31. S.R. Feldman, S.M. Ravis, A.B. Fleischer, A. McMichael, E. Jones, and R. Kaplan Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis J Cutan Med Surg 5 2001 386 389
32. D.E. Vanderploeg, R.C. Cornell, R. Binder, J.S. Weintraub, M. Jarrat, and M.L. Jones Clinical trial in scalp psorisis. Mometasone furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily Acta Ther 15 1989 145 152
33. J.M. Swinehart, J.R. Barkoff, D. Dvorkin, G. Fisher, and E. Peets Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis Int J Dermatol 28 1989 680 681
34. P. Reygagne, U. Mrowietz, J. Decroix, F.B. de Waard-van der Spek, L.O. Acebes, and A. Figueiredo Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis J Dermatolog Treat 16 2005 31 36
35. M.R. Klaber, P.E. Hutchinson, A. Pelvis-Leftick, K. Kragballe, T.L. Reunala, and P.C. van de Kerkhof Comparative effects of calcipotriol solution (50 micrograms/mL) and betamethasone 17-valerate solution (1 mg/mL) in the treatment of scalp psoriasis Br J Dermatol 131 1994 678 683
36. C.E. Griffiths, A.Y. Finlay, C.J. Fleming, J.N. Barrer, F. Mizzi, and S. Arsonnaud A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis J Dermatolog Treat 17 2006 90 95
37. L. Hillstrm, L. Pettersson, and L. Svensson Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp J Int Med Res 10 1982 419 422
38. P. Andres, M. Poncet, S. Farzaneh, and P. Soto Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary- adrenal axis supresin, atrophogenicity, and ocular safety in subjects with scalp psoriasis J Drugs Dermatol 5 2006 328 332
39. A. Lassus Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison Curr Med Res Opin 4 1976 365 367
40. H. Bovenschen, and P. van de Kerkhof Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice J Eur Acad Dermatol Venereol 24 2010 439 444
41. J. Tan, R. Thomas, B. Wang, D. Gratton, R. Vender, and N. Kerrouche Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis Cutis 83 2009 157 164
42. 3 anologue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes Arch Dermatol Res 282 1990 164 167
43. C. Green, M. Ganpule, D. Harris, G. Kavanagh, C. Kennedy, and R. Mallet Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp Br J Dermatol 130 1994 483 487
44. ®) shampoo, and long-term experience J Dermatolog Treat 11 2000 21 28
45. G.A. Duweb, O. Abuzariba, M. Rahim, M. Al-Taweel, and S.A. Abdulla Scalp psoriasis: topical calcipotriol 50 μg/g/ml solution vs betamethasone valerate 1% solution Int J Clin Pharmacol Res 20 2000 65 68
46. S. Emaitig, M. Alyazachi, A. Bashir, and G. Duweb Calcipotriol solution vs. betamethasone and salicylic acid solution in the treatment of scalp psoriasis J Eur Acad Dermatol Venereol 18 Suppl 2 2004 262
47. C. Barrett, D. Lowson, and K.J. Blades Limited benefit of combined use of tar-based shampoo with 50 mg/ml calcipotriol solution in scalp psoriasis J Dermatol Treat 16 2005 175
48. T. Ruzicka, and C. Trompke Behandlung der Kopfhaut-Psoriasis. Gute Wirksamkeit und Sicherheit durch Tacalcitol-Emulsion Hautarzt 55 2004 165 170
49. L. Barnes, P. Altmeyer, L. Frstrm, and M.H. Stenstrm Long-term treatment of psoriasis with calcipotriol scalp solution and cream Eur J Dermatol 10 2000 199 204
50. J. Faergemann, U. Diehl, L. Bergfelt, A. Brodd, B. Edmar, and K. Hersle Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol Acta Derm Venereol 83 2003 438 441
51. C.A. Ramsay, J. Berth-Jones, G. Brundin, W.J. Cunliffe, L. Dubertret, and P.C. Van de Kerkhof Long-term use of topical calcipotriol in chronic plaque psoriasis Dermatology 189 1994 260 264
52. J. Koo Vitamin D and scalp psoriasis Cutis 70 Suppl 5 2002 21 24
53. K. Kragballe, and P.C. Van de Kerkhof Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis J Eur Acad Dermatol Venereol 20 2006 39 44
54. N. Cassano, and G.A. Vena Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product Acta Derm Venereol 87 2007 85 86
55. A.M. Downs Dovobet ointment under occlusion overnight for troublesome scalp psoriasis Acta Derm Venereol 86 2006 57 58
56. ® ointment Br J Dermatol 151 Supl 68 2004 52 53
57. C. Buckley, V. Hoffmann, J. Shapiro, S. Saari, F. Cambazard, and M. Milsgaard Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study Dermatology 217 2008 107 113
58. G.B.E. Jemec, C. Ganslandt, J.P. Ortonne, Y. Poulin, A.D. Burden, and P. de Unamuno A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial J Am Acad Dermatol 59 2008 455 463
59. P.C.M. van de Kerkhof, V. Hoffmann, A. Anstey, L. Barnes, C. Bolduc, and K. Reich A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial Br J Dermatol 160 2009 170 176
60. S. Tyring, and A. Bibby Calcipotrione/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in hispanic/latino and black/african american patients J Am Acad Dermatol 58 Suppl 2 2008 AB125
61. J.P. Ortonne, C. Ganslandt, J. Tan, P. Nordin, K. Kragballe, and S. Segaert Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial J Eur Acad Dermatol Venereol 23 2009 919 926
62. K. Kragballe, V. Hoffmann, J.P. Ortonne, J. Tan, P. Nordin, and S. Segaert Efficay and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial Br J Dermatol 161 2009 159 166
63. T.A. Luger, F. Cambazard, F.G. Larsen, M. Bourcier, G. Gupta, and F. Clonier A study of the safety of efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis Dermatology 217 2008 321 328
64. J.L. López Estebaranz Tratamiento local de la psoriasis del cuero cabelludo del adulto Monogr Dermatol 22 2009 55 60
65. S.M. Going, B.M. Guyer, D.R. Jarvie, and J.A. Hunter Salicylic acid gel for scalp psoriasis Clin Exp Dermatol 11 1986 260 262
66. A. Langner, H. Wolska, and P. Hebborn Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations Cutis 32 1983 290 296
67. A. McGill, A. Frank, N. Emmett, D.M. Turnbull, M.A. Birch-Machin, and N.J. Reynolds The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondra, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory component mitichondria FASEB J 19 2005 1012 1024
68. A. Wulff-Woesten, D. Ohlendorf, B.M. Henz, and N. Haas Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psorioasis of the scalp Skin Pharmacol Physiol 17 2004 91 97
69. H.P. Gollnick, A.F. Finzi, R. Marks, J.N. Barker, C. Jansen, and J. Revuz optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM) Dermatology 199 1999 40 46
70. E. Gueho, T. Boekhout, H.R. Ashbee, J. Guillot, A. Van Belkum, and J. Faergemann The role of the Malassezia species in the ecology of human skin and as a pathogens Med Mycol 36 Suppl 1 1998 220 229
71. R.B. Warren, B.C. Brown, and C.E. Griffiths Topical treatment for scalp psoriasis Drugs 68 2008 2293 2302
72. A. Shemer, N. Nathansohn, B. Kaplan, G. Weiss, N. Newman, and H. Trau Treatment of scalp seborrheic dermatitis and psoriasis with an oinment of 40% urea and 1% bifonazole Int J Dermatol 39 2000 532 534
73. C.S. Jury, L. McHugh, G.S. Shankland, and A.D. Burden A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis J Dermatol Treat 11 2000 85 89
74. J. Faergemann, U. Diehl, L. Bergfelt, A. Brodd, B. Edmar, and K. Hersle Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol Acta Derm Venereol 83 2003 438 441
75. L.A. Wheeler, M.D. Saperstein, and N.J. Lowe Mutagenicity of urine from psoriatic patients undergoing treatment with coal tar and ultraviolet light J Invest Dermatol 77 1981 181 185
76. S.H. Yuspa Cutaneous chemical carcinogenesis J Am Acad Dermatol 15 1986 1031 1044
77. C. Johnson, B. Edison, I. Brouda, and B. Green A novel LCD (coal tar) solution for psoriasis does not discolour naturally light or color-processed hair in an exaggerated exposure test model J Cosmet Dermatol 8 2009 211 215
78. J.M. Carrascosa, F. Vanaclocha, L. Borrego, E. Fernndez-López, A. Fuertes, and L. Rodrguez-Fernndez-Freire Revisión actualizada del tratamiento tpico de la psoriasis. Documento de Consenso Actas Dermosifiliogr 100 2009 190 200
79. T.M. Dando, and K. Wellington Topical tazarotene: a review of its use in the treatment of plaque psoriasis Am J Clin Dermatol 6 2005 255 272
80. C.R. Taylor, and A.L. Racette A 308-nm excimer laser for the treatment of scalp psoriasis Lasers Surg Med 34 2004 136 140
81. L.K. Dotterud, and R. Braun UV-B comb versus betamethasone solution in scalp psoriasis Tidsskr Nor Laegeforen 120 2000 1858 1859
82. B. Lindelf, and A. Johannesson Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial Br J Dermatol 119 1988 241 244
83. A. García Dez Tratamiento sistmico de la psoriasis del cuero cabelludo Monogr Dermatol 22 2009 61 66
84. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Boggie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
85. I. Flystrm, B. Stenberg, A. Svensson, and I.M. Bergbrant Methotrexate vs cyclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 158 2008 116 121
86. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortrone Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566
87. J. Koo A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporine, Neoral and Sandimmun, in patients with psoriasis Br J Dermatol 139 1998 88 95
88. C.N. Ellis, M.S. Fradin, J.M. Messana, M.D. Brown, M.T. Siegel, and A.H. Hartley Cyclosporin for plaque-type psoriasis. Results of a multidose, double-blind trial N Eng J Med 324 1991 277 284
89. K. Kragballe, C.T. Cansen, J.M. Geiger, J.R. Bjerke, E.S. Falk, and L. Gip A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study Acta Derm Venereol 69 1989 35 40
90. D.J. Pearce, S. Klinger, K.K. Ziel, E.J. Murad, R. Rowell, and S.R. Feldman Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis Arch Dermatol 142 2006 1000 1004
91. P.J. Altmeyer, U. Matthes, F. Pawlak, K. Hoffmann, P.J. Frosch, and P. Ruppert Antipsoriatic effect of fumaric acid derivates. Results of a multicenter double-blind study in 100 patients J Am Acad Dermatol 30 1994 977 981
92. H. Gollnick, P. Altmeyer, R. Kaufmann, J. Ring, E. Christophers, and S. Pavel Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris Dermatology 205 2002 46 53
93. K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, and S. Kang Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606
94. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
95. Thai D, Khemis A, Ghislain P-D, Arenberger P, Kragballe K, Saurat J-H, et al. Adalimumab plus topical treatment (calcipotriol/beta-methasone) in the treatment of moderate to severe psoriasis Effects on skin, scalp, and nails: Results from BELIEVE. 18 Congreso de la Academia Europea de Dermatología y Venereología (EADV), Berln, 2009; Abstract P824.
96. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
97. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Eng J Med 349 2003 2014 2022
98. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
99. S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 2006 29 35
100. Ortonne JP, Strohal R, Dauden E, Robertson D, Pedersen R, Molta C. Etanercept treatment for up to 54 weeks sustain scalp improvement in patients with moderate to severe psoriasis: Results of the Crystel Study. 5 Simposio de primavera de la Academia Europea de Dermatología y Venereología (EADV), Estambul, 2225 mayo 2008. Abstract #FC08-5.
101. U. Chaudari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.J. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847
102. A.B. Gottlieb, R. Evans, S. Li, T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
103. J.P. Ortonne Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients wirh chronic plaque psoriasis J Eur Acad Dermatol Venereol 17 Suppl 2 2003 12 16
104. C.H. Gribetz, R. Blum, C. Brady, S. Cohen, and M. Lebwohl An extended 16-week course of alefacept in the treatment oc chronic plaque psoriasis J Am Acad Dermatol 53 2005 73 75
105. J. Krell, C. Nelson, L. Spencer, and S. Miller An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis J Am Acad Dermatol 58 2008 609 616
106. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang for the PHOENIX 1 Study Investigators Efficay and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
107. K. Papp, R.G. Langley, R. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding for the PHOENIX 2 Study Investigators Efficay and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
108. L. El Shabrawi-Caelen, M. La Placa, C. Vincenci, T. Haidn, R. Muelleger, and A. Tosti Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers Inflamm Bowel Dis 16 2010 182 183
109. B.L. Barlett, and S.K. Tyring Ustekinumab for chronic plaque psoriasis Lancet 371 2008 1639 1640